Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (3883)	9/22/1999 6:44:00 AM
From: JDN	Read Replies (2) \| Respond to of 10293

Dear Bill: Regarding COST there was HUGE volume yesterday and stock up in a really poor market. Do you know why the volume was so large? Regarding GUMM I saw an announcement in the news last night that may be a much larger threat to ZICAMS success than anything related to those studies. That is GLAXO and another Drug Company (Rochelle ??) are about to release THEIR claim to the cure for the common cold (which of course requires a prescription AND a Dr's office visit). Their products will be released with a huge marketing campaign and I suspect Drs also will be pushing it for OBVIOUS reasons. Zicam whether it works or not may get lost in the noise. JDN

To: Bill Wexler who wrote (3883)	9/22/1999 10:18:00 AM
From: JDN	Respond to of 10293

Dear Bill: Based upon your recommendation I picked up a couple hundred shares of COST at the opening at 66 7/8. Was that a guarantee? haha. I did some investigation into why the huge volume yesterday. Turns out some funds seemed to be selling while others were buying, result a lot of shares changed hands and stock price held firm. Personally, I consider that a good thing, dont you? JDN